Biomerica (NASDAQ:BMRA) issued its earnings results on Wednesday. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.03), Fidelity Earnings reports. Biomerica had a negative return on equity of 40.08% and a negative net margin of 52.42%.
NASDAQ:BMRA traded down $0.36 during trading on Friday, reaching $5.70. The company’s stock had a trading volume of 419,885 shares, compared to its average volume of 1,561,208. The firm has a market cap of $66.99 million, a price-to-earnings ratio of -17.66 and a beta of -0.47. Biomerica has a 12 month low of $2.05 and a 12 month high of $23.39. The firm has a 50 day moving average of $5.75 and a 200-day moving average of $7.05.
In related news, Director Catherine Coste purchased 9,100 shares of Biomerica stock in a transaction that occurred on Monday, October 26th. The stock was bought at an average price of $5.45 per share, for a total transaction of $49,595.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 23.70% of the company’s stock.
Biomerica, Inc, a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations.
Recommended Story: How to Invest in a Bull Market
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.